Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Projected $20 Mil. In 2013 Biosimilar User Fees Translates Into 68 More Staffers

This article was originally published in The Pink Sheet Daily

Executive Summary

Administration’s proposed fiscal year 2013 spending plan includes $4.5 billion for FDA, with $2 billion or 44% provided by various user fees.


Related Content

Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?
FDA Cuts Priority Review Voucher Fee By 32%; J&J In Line For Next Voucher?
GOP Drug Shortage Strategy Pushes FDA Reform, Reimbursement Over Notification
PDUFA V: Can FDA Fight Off Mission Creep This Cycle?
Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections
User Fee Triggers Require Care In Unfriendly Budget Environment, Ventimiglia Says
FDA’s Generic Drug Office Goes On Diet Before Swallowing User Fees
Priority Review Voucher Value Still Confounds, But Remains An Incentive For Sponsors
FDA Wants Authority To Enforce Track-And-Trace System For Drugs
How "Clean" Will PDFUA V Be? Rep. Pitts Explains His Vacuuming Technique


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts